Novartis Venture Fund has helped seed a T-cell drug developer founded from Seattle Children's Hospital, Benaroya Research Institute and MIGAL Galilee.
GentiBio, a US-based T-cell therapy developer based on insights from multiple research centres, closed a $20m seed round yesterday co-led by Novartis Venture Fund, the corporate venturing unit for pharmaceutical firm Novartis.
The round was co-led by healthcare-focused investment firm OrbiMed and RA Capital Management.
GentiBio plans to develop drugs that restore immune system function using regulatory T-cells engineered using the CD4 subpopulation, which is thought to be in greater supply than alternative production sources.
A scarcity…
